What is Noble Financial’s Estimate for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at Noble Financial issued their Q1 2026 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research report issued on Monday, March 23rd. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.91) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.67.

Eledon Pharmaceuticals Stock Up 1.4%

NASDAQ:ELDN opened at $2.96 on Wednesday. The firm’s fifty day simple moving average is $2.42 and its 200 day simple moving average is $2.35. The stock has a market cap of $224.52 million, a P/E ratio of -5.69 and a beta of 0.84. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Thursday, March 19th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.10.

Institutional Trading of Eledon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. increased its position in Eledon Pharmaceuticals by 95.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 71,666 shares of the company’s stock valued at $108,000 after buying an additional 35,000 shares in the last quarter. Kera Capital Partners Inc. grew its stake in shares of Eledon Pharmaceuticals by 54.3% in the fourth quarter. Kera Capital Partners Inc. now owns 39,770 shares of the company’s stock worth $60,000 after acquiring an additional 14,000 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter worth $39,000. XTX Topco Ltd increased its holdings in shares of Eledon Pharmaceuticals by 867.1% during the fourth quarter. XTX Topco Ltd now owns 124,247 shares of the company’s stock valued at $188,000 after acquiring an additional 111,399 shares in the last quarter. Finally, Zimmer Partners LP raised its position in shares of Eledon Pharmaceuticals by 30.6% in the 4th quarter. Zimmer Partners LP now owns 2,384,228 shares of the company’s stock worth $3,600,000 after purchasing an additional 559,228 shares during the last quarter. 56.77% of the stock is owned by institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.